共 50 条
- [5] Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study [J]. FRONTIERS IN NEUROLOGY, 2022, 13
- [8] Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2022, 30 (03): : 360 - 371